StockNews.com Initiates Coverage on Can-Fite BioPharma (NYSE:CANF)

Research analysts at StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, March 18th.

Can-Fite BioPharma Price Performance

Shares of NYSE:CANF opened at $1.41 on Tuesday. The firm has a market capitalization of $4.99 million, a price-to-earnings ratio of -0.79 and a beta of 1.37. The business’s 50 day moving average price is $1.56 and its 200-day moving average price is $1.79. Can-Fite BioPharma has a 1 year low of $1.29 and a 1 year high of $4.69.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers raised its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the quarter. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.